For health care professionals

SCCA is proud that our own Stephanie Lee, MD, MPH served as the 2020 president of the American Society of Hematology (ASH). Dr. Lee is a highly regarded expert in graft-versus-host disease, as well as blood and bone marrow diseases. We asked Dr. Lee about her time as president of ASH and what she sees as the direction of oncology care in the future.

For years, sarcoma treatment was formulaic: Patients would cycle through standard chemotherapies and, if those were ineffective, there were few other options. But the sarcoma landscape has changed dramatically, with a surge of innovative drugs and investigational approaches that are creating hope against sarcoma and extending survival for some patients. 

In a large randomized clinical trial, researchers evaluated the immunotherapy drug avelumab for patients with advanced urothelial cancer. The findings of the trial, called the JAVELIN Bladder 100 study, are “very exciting," even "practice-changing,” said Dr. Petros Grivas, of SCCA, co-leader of this global, industry-sponsored trial.

SCCA recently launched a Thoracic Oncology Multispecialty Clinic (TOMC) to bring multidisciplinary care to patients with lung cancer and other thoracic cancers. The clinic unites top thoracic surgeons, radiation oncologists and medical oncologists to evaluate patients and design customized treatment plans.